NHRI Enters Technology Transfer Agreement of DBPR215 with Jiayi Biomedical Co., Ltd. IBPR 2021-08-16 2021-08-16News & Events National Health Research Institutes (NHRI) and Jia… Continue reading
National Health Research Institutes Announces the Initiation of Phase I Clinical Trial of DBPR115, A Novel Small-molecule Drug Conjugate (SMDC), in Taiwan IBPR 2021-08-16 2021-08-16News & Events With budget supporting from Ministry of Economic A… Continue reading
NHRI Enters Technology Transfer Agreement of DBPR211 with Applied Biopharma LLC, wholly owned by Agentix Corp. (AGTX) in the US IBPR 2021-08-06 2021-10-12News & Events National Health Research Institutes (NHRI) and App… Continue reading
Congratulations! Dr. Ta-Yuan Chang is elected as a member of the U.S. National Academy of Sciences. IBPR 2021-04-27 2021-04-28News & Events We are honored to announce a good news that Profes… Continue reading
A Safer Opioid Painkiller with Low Side-Effects─NHRI has discovered a series of opioid receptor/nociception receptor dual agonists with fast and potent antinociception, fewer side-effects than morphine IBPR 2020-11-23 2020-11-23News & Events The Ministry of Science and Technology has present… Continue reading
Muscle age and lifespan: beyond physiological strength-NHRI has discovered a direct link between skeletal muscle aging and mortality through thermogenic and metabolic abnormalities IBPR 2020-10-30 2020-11-05News & Events Using genetic modified mouse models, research at t… Continue reading
NHRI licenses DBPR216, an anti-cancer developmental drug candidate, to Taivex Therapeutics Corp IBPR 2019-04-17 2019-04-17News & Events The National Health Research Institutes (NHRI) and… Continue reading
National Health Research Institutes Announces FDA approval of Investigational New Drug (IND) Applications for Two Novel Small Molecules, DBPR211 and DBPR114 IBPR 2017-12-01 2018-01-16News & Events Institute of Biotechnology and Pharmaceutical Rese… Continue reading
DBPR211, a novel small-molecule anti-type 2 diabetes drug candidate, was approved for Phase I clinical study by the US Food and Drug Administration (FDA) IBPR 2016-07-06 2016-07-06News & Events Institute of Biotechnology and Pharmaceutical Rese… Continue reading
DBPR112, a novel small-molecule anticancer drug candidate, was approved for Phase I clinical study by the US Food and Drug Administration (FDA) IBPR 2016-05-06 2016-05-06News & Events The Investigational New Drug (IND) application of … Continue reading
